title: When Good Goes Awry: The Aggregation of Protein Therapeutics.
abstract: Protein therapeutics are playing an increasingly important role in treatment of a variety of human diseases. However, like the rest of proteins, they are susceptible to aggregation. Aggregation of proteinaceous pharmaceuticals can cause a loss of efficacy and, potentially, cytotoxicity and an immunogenic response. This review describes various ways protein therapeutics aggregate and a variety of approaches taken to prevent or minimize this process.
authors.affiliation: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. United States.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Redington
authors.affiliation: USF Health Byrd Alzheimer`s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. United States.
authors.forename: Leonid
authors.initials: L
authors.lastname: Breydo
authors.affiliation: Department of Molecular Medicine Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC07, Tampa, Florida 33612. United States.
authors.forename: Vladimir N
authors.initials: VN
authors.lastname: Uversky
mesh_terms: D000911:Antibodies, Monoclonal; D004339:Drug Compounding; D004355:Drug Stability; D004356:Drug Storage; D005934:Glucagon; D006801:Humans; D007328:Insulin; D066329:Protein Aggregates
chemical_list: D000911:Antibodies, Monoclonal; D007328:Insulin; D066329:Protein Aggregates; D005934:Glucagon
keywords: Aggregation; antibodies; delivery; formulation; glucagon; insulin; storage